Codexis (CDXS) Change in Accured Expenses (2010 - 2020)
Codexis (CDXS) posted quarterly Change in Accured Expenses of $3.9 million for Q4 2020, up 39.04% year-over-year from $2.8 million in Q1 2020, and up 305.85% quarter-over-quarter from -$1.9 million in Q1 2020.
Codexis (CDXS) Change in Accured Expenses (2010 - 2020) Analysis & Trends
Codexis' Change in Accured Expenses history runs 11 years deep, the most recent figure standing at $3.9 million for Q4 2020.
- In Q4 2020, Change in Accured Expenses rose 39.04% year-over-year to $3.9 million; the TTM figure through Dec 2020 stood at $4.9 million (up 122.9% YoY), while the FY2022 annual figure was $6.0 million, down 9.0% from the prior year.
- Change in Accured Expenses for Q4 2020 stood at $3.9 million, up from -$1.9 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $3.9 million in Q4 2020, with the low at -$1.9 million in Q2 2019.
- The 5-year median for Change in Accured Expenses is $424500.0 (2018), against an average of $393222.2.
- The sharpest annual moves came in 2017 and 2019: Change in Accured Expenses jumped 472.64% in 2017, then plunged 654.72% in 2019.
- Codexis' Change in Accured Expenses stood at $923000.0 in 2016, then sank by 196.21% to -$888000.0 in 2017, then advanced by 6.53% to -$830000.0 in 2018, then soared by 435.18% to $2.8 million in 2019, then jumped by 39.04% to $3.9 million in 2020.
- Business Quant data shows CDXS's Change in Accured Expenses at $3.9 million in Q4 2020, -$1.9 million in Q1 2020, and $2.8 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Codexis | 152.06 Mn | 97.14 Mn | 11.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 3.87 Mn |
| Dec 31, 2020 | 3.87 Mn |
| Mar 31, 2020 | -1.88 Mn |
| Mar 31, 2020 | -1.88 Mn |
| Dec 31, 2019 | 2.78 Mn |
| Dec 31, 2019 | 2.78 Mn |
| Sep 30, 2019 | 144,000.00 |
| Sep 30, 2019 | 144,000.00 |
| Jun 30, 2019 | -1.92 Mn |
| Jun 30, 2019 | -1.92 Mn |
| Mar 31, 2019 | 1.20 Mn |
| Mar 31, 2019 | 1.20 Mn |
| Dec 31, 2018 | -830,000.00 |
| Dec 31, 2018 | -830,000.00 |
| Sep 30, 2018 | 881,000.00 |
| Sep 30, 2018 | 881,000.00 |
| Jun 30, 2018 | -254,000.00 |
| Jun 30, 2018 | -254,000.00 |
| Mar 31, 2018 | 705,000.00 |
| Mar 31, 2018 | 705,000.00 |